In the United States, there has been a rapid growth in the number of cases and coronavirus disease 2019 (COVID-19)--related deaths with a tremendous impact on the organization and function of medical care. Healthcare systems, including cancer centers, are attempting to find balance, minimizing viral transmission and protecting staff and patients without compromising the delivery of patient care.[@bib1] ^,^ [@bib2] The literature on COVID-19 and cancer is quickly growing as authors attempt to educate the oncologic community with their experience in an area in which data are limited. Early reports suggest that people with cancer may experience worse outcomes from COVID-19, including higher risk of admission to intensive care units, requirement for invasive ventilation, and death.[@bib3] ^,^ [@bib4] However, these studies are limited by small sample size, heterogeneous cancer types, and confounding variables including other medical comorbidities.AJOG at a GlanceWhy was this study conducted?The goal of this survey was to evaluate the experience of women with ovarian cancer during the coronavirus disease 2019 (COVID-19) pandemic, assessing the effects of the pandemic on cancer-directed treatment and quality of life (QOL).Key findingsOf women with current or prior ovarian cancer, 33% experienced a delay in cancer care during the COVID-19 pandemic. During the pandemic, 89% reported significant cancer worry. Younger age, presumed immunocompromise, and delay in care were associated with a significant increase in cancer worry, anxiety, and depression.What does this add to what is known?Literature on the experience of patients with cancer during COVID-19 is limited; this study provides the perspective of ovarian cancer survivors on cancer-directed care and QOL.

The provision of relevant, understandable, and realistic information is considered a dimension of quality in cancer care. We have shown previously that women with ovarian cancer find communication between survivors and physicians to be an essential component of care.[@bib5], [@bib6], [@bib7], [@bib8] As oncology providers and survivors struggle to balance plausible fears of COVID-19 and cancer treatment with the consequences of delaying cancer care, communication between patients and physicians will likely become only more critical.[@bib10], [@bib11], [@bib12], [@bib9] Physicians treating women with ovarian cancer must not only remain well informed on the relationship between COVID-19 and cancer but also appreciate the unique challenges experienced by these survivors during this unprecedented time. The goal of this survey was to evaluate the experience of women with ovarian cancer during the COVID-19 pandemic, assessing the effects of the pandemic on cancer-directed treatment and quality of life (QOL).

Methods {#sec1}
=======

This study was approved by the Weill Cornell Medical College and Icahn School of Medicine at Mount Sinai institutional review boards. The COVID-19 Concern Survey combined questions to assess participant demographics and cancer history, cancer-directed treatment during the COVID-19 pandemic, and QOL. The validated QOL survey instruments included the Hospital Anxiety and Depression Scale (HADS)[@bib13] and the Cancer Worry Scale (CWS).[@bib14] ^,^ [@bib15] The HADS is a questionnaire investigating anxiety (HADS-A) and depression (HADS-D). Both HADS subscales consist of 7 items answered on a 4-point Likert scale, resulting in scores from 0 to 21. A score of 0 to 7 is considered normal anxiety or depression; 8 to 10, borderline abnormal; and 11 and 21, abnormal. The CWS is a scale to assess cancer-specific distress, consisting of 6 items answered on a 4-point Likert scale, resulting in scores ranging from 6 to 24. The higher the score, the higher the level of cancer worry, with a cutoff of 10 or greater for significant cancer worry.

The COVID-19 Concern Survey consisted of 65 questions and was distributed online via survivor networks, including the Ovarian Cancer Research Alliance and Community Partners, National Ovarian Cancer Coalition, SHARE Cancer Support, Sandy Rollman Foundation, Woman to Woman Program and Tina's Wish, and social media via Twitter and Facebook groups, including \#gyncsm (Gynecologic Cancer Social Media Community), Ovarian Cancer 101, Rare Ovarian Cancer Subtypes Team, Sisterhood of Ovarian Cancer Survivors, and Teal Life -- Ovarian Cancer Awareness. The survey was created by the advocates of ovarian cancer and oncology providers to capture the experience of the COVID-19 pandemic among women with current or prior ovarian cancer. The survey was available for 14 days, from March 30, 2020, to April 13, 2020. This 2-week period was selected on the basis of prior experience with response volume to online survivor network surveys, with the goal of achieving a high level of participation and rapid dissemination of findings to women with ovarian cancer and providers.[@bib7] ^,^ [@bib16] The survey was completed online by self-identified ovarian cancer survivors, including any woman with a current or prior diagnosis of ovarian cancer regardless of treatment status. Participation was anonymous and consent was provided electronically. Participants provided their state of residence, and states were coded based on the Centers for Disease Control and Prevention (CDC) designation as high, intermediate, and low case volume on April 17, 2020.[@bib17]

Statistical methods {#sec1.1}
-------------------

The distribution of continuous variables was tested for normality via the Shapiro-Wilk normality test. Univariate tests were applied based on whether the variable of interest was distributed normally (ie, *t*-test and analysis of variance) or not normally (ie, Mann-Whitney *U* test and Kruskal-Wallis test). Associations between categorical variables were evaluated using the chi-square test or Fisher exact tests, as appropriate for category size. Kappa coefficients were used to examine collinearity between variables. For assessment of QOL, validated surveys were scored per the survey protocol. Multivariable linear regression analysis was explored to evaluate the independent effect of age less than 65 years, living alone, COVID-19 case volume by state, cancer stage, scheduled for cancer treatment or surgery, delay in oncology care, medical comorbidities, access to counseling, self-described as immunocompromised, and the use of telemedicine for oncology care on the QOL survey scores (CWS, HADS-A, and HADS-D). Statistical significance was evaluated at the .05 alpha level, and 95% confidence intervals were calculated for all obtained estimates. Data were analyzed using SPSS Statistical software (version 20, SPSS, INC, 2011) and R (version 3.6.1, R Foundation for Statistical Computing, 2019).

Results {#sec2}
=======

A total of 603 women visited the survey website between March 30, 2020, and April 13, 2020, and 555 (92%) completed the survey after providing electronic consent. The median age of participants was 58 years (range, 20--85). Most participants self-identified as white (469, 93.8%) ([Table 1](#tbl1){ref-type="table"} ). There were participants from 41 states and 5 countries outside of the United States. A total of 313 participants (65.1%) came from states designated as high COVID-19 case volume by CDC ([Figure 1](#fig1){ref-type="fig"} ).[@bib17] A total of 92 participants (16.6%) reported having a noncancer medical comorbidity, 45 participants (8.1%) reported having diabetes, 30 (5.4%) chronic lung disease, 21 (3.8%) chronic kidney disease, and 13 (2.3%) coronary artery disease.Table 1Participants' demographics and cancer historyCharacteristicsN%Age (n=511[a](#tbl1fna){ref-type="table-fn"}) \<65 y37673.58 ≥65 y13526.41Race (n=500[a](#tbl1fna){ref-type="table-fn"}) American Indian or Alaska Native30.60 Asian or Asian American102.00 Black or African American122.40 White46993.80 Other61.20Ethnicity (n=495[a](#tbl1fna){ref-type="table-fn"}) Hispanic or Latino142.83 Not Hispanic or Latino48197.17Current relationship status (n=505[a](#tbl1fna){ref-type="table-fn"}) Married/civil union/domestic partnership34067.33 Divorced/widowed/separated8717.23 Single7815.45Living alone (n=507[a](#tbl1fna){ref-type="table-fn"}) Yes10119.92 No40680.08Highest level of education (n=506[a](#tbl1fna){ref-type="table-fn"}) Less than high school degree10.20 High school degree or equivalent387.51 Some college13727.08 Bachelor degree16933.40 Graduate degree16131.82Ovarian cancer stage (n=505[a](#tbl1fna){ref-type="table-fn"}) I/II17033.66 III/IV32163.56 Uncertain142.77Completed first-line treatment (n=505[a](#tbl1fna){ref-type="table-fn"}) Yes47694.26 No203.96 Uncertain91.78Currently receiving treatment (n=501[a](#tbl1fna){ref-type="table-fn"}) Yes21743.31 No28456.69[^1][^2]Figure 1Distribution of COVID-19 case volume of participants' states by the Centers for Disease Control and Prevention designation as high, intermediate, and low*COVID-19*, coronavirus disease 2019.*Frey et al. Ovarian cancer during the COVID-19 pandemic. Am J Obstet Gynecol 2020*.

At the time of survey completion, 217 (43.3%) participants were receiving cancer-directed therapy. Treatments included intravenous chemotherapy (61, 28.1%), oral chemotherapy (12, 5.5%), poly (ADP-ribose) polymerase (PARP) inhibitor therapy (70, 32.3%), immunotherapy (10, 4.6%), PARP inhibitor combined with immunotherapy (3, 1.4%), hormonal therapy (25, 11.5%), antiangiogenic therapy (29, 13.4%), other targeted therapy (3, 1.4%), and radiation (4, 1.8%). Overall, 175 participants (33.3%) reported a delay in some component of their cancer care. Among the 217 participants scheduled for nonsurgical cancer-directed therapy, 18 (8.3%) reported that their treatment was postponed and 199 (91.7%) underwent treatment without delay. Planned treatments that were postponed included intravenous chemotherapy (7), oral chemotherapy (1), PARP inhibitor therapy (4), immunotherapy (1), hormonal therapy (3), antiangiogenic therapy (1), and other targeted therapy (1). A total of 38 participants (6.9%) reported that they were scheduled for surgical treatment of ovarian cancer. Among these women, 10 (26.3%) reported that the surgery was delayed because of COVID-19. A total of 133 participants (24.0%) reported that an appointment with their gynecologic oncologist was postponed, 84 participants (15.1%) reported that a cancer-related laboratory test was postponed, and 53 participants (9.6%) reported that cancer-related imaging was postponed.

Of 503 participants, 252 (50.1%) responded that they self-described as immunocompromised, with 129 (25.6%) not self-describing as immunocompromised and 122 (24.3%) uncertain. The correlation between self-described as immunocompromised and receiving active cancer treatment was modest (kappa=0.39). Of 516 responders, 129 (25.0%) reported they had used telemedicine for gynecologic oncology care, with 224 (43.4%) reporting they had not and 163 (31.6%) uncertain. When asked whether or not they had access to online or in-person counseling, 287 (55.8%) of the 514 responders said yes, 111 (21.6%) said no, and 116 (22.6%) were uncertain. Of 517 respondents, 415 (80.3%) participated in networks for ovarian cancer survivors, 89 (17.2%) did not, and 13 (2.5%) were uncertain. Of note, when participants were asked about participation in telemedicine, counseling, and survivor networks, the services were not further defined.

QOL was measured with 2 survey instruments that have been validated in the oncology literature, CWS and HADS. Among the 552 participants completing CWS, the median CWS score was 14 (range, 6--24). A total of 489 participants (88.6%) reported significant cancer worry. Among the 555 participants completing HADS, the median anxiety score was 8 (range, 0--21) and the median depression score was 5 (range, 0--21). A total of 285 participants (51.4%) reported borderline or abnormal anxiety (borderline: 155, 27.9%; abnormal: 130, 23.4%) and 147 (26.5%) borderline or abnormal depression (borderline: 105, 18.9%; abnormal: 42, 7.6%).

The demographics, cancer, and treatment history of participants were evaluated for associations with cancer worry, anxiety, and depression. On univariate analysis, age less than 65 years, being scheduled for cancer treatment or cancer surgery, delay in oncology care, self-described as immunocompromised, and use of telemedicine were all associated with higher levels of cancer worry. Higher anxiety scores were associated with age less than 65 years and self-described as immunocompromised. Higher depression scores were associated with age less than 65 years, being scheduled for cancer surgery, delay in oncology care, self-described as immunocompromised, and use of telemedicine. Depression scores were significantly lower in participants reporting access to counseling ([Table 2](#tbl2){ref-type="table"} ).Table 2Univariate analysis of predictors of cancer worry, anxiety, and depressionPredictorCancer Worry ScaleHADS-AnxietyHADS-DepressionNMedianMinMax*P* valueNMedianMinMax*P* valueNMedianMinMax*P* valueAge\<.001.003.041 ≥65 y13513.06231357.00181354.0021 \<65 y37315.06243768.00213765.0019Living alone.599.619.129 No40414.06244068.00204065.0021 Yes10014.06231018.00211015.0019State.756.84.568 High case volume31214.06243138.00203135.0017 Moderate case volume15614.56241578.00211575.0021 Low case volume1114.0921117.0113114.0111Cancer stage.106.121.672 110913.0622109109 26115.0624619.0021615.0021 324114.06242447.00202444.0019 47715.0623778.0018775.0015 Unknown1415.5724147.5115146.0012Scheduled for cancer treatment\<.001.645.062 No28413.06242848.00202844.0019 Yes21415.56242178.00212175.0019Scheduled for cancer surgery.03.304.022 No48514.06244888.00214885.0019 Yes3817.0623389.0118387.0021Delay in oncology care.002.068.032 No35014.06243518.00203515.0021 Yes17315.07241758.00211755.0019Medical Comorbidity (noncancer).443.233.071 No43114.06244348.00214345.0021 Yes9215.0824928.0020925.5018Access to counseling.142.136.026 No11015.56241119.00201116.0021 Yes28514.06242878.00212875.0019 Uncertain11615.06241168.00181165.0019Self-described as immunocompromised\<.001.05\<.001 No12812.56231297.00181294.0017 Yes25016.06242528.00212525.0021 Uncertain12214.06231228.00201224.0019Use of telemedicine\<.001.139.025 No22413.06242247.00202244.0021 Yes12916.06241298.00211295.0019 Uncertain16315.08241638.00201634.0015[^3][^4]

We performed a multivariable linear regression model incorporating age less than 65 years, living alone, COVID-19 case volume by state, cancer stage, scheduled for cancer treatment or surgery, delay in oncology care, medical comorbidities, access to counseling, self-described as immunocompromised, and use of telemedicine for oncology care. On multivariable analysis, cancer worry was independently associated with age less than 65 years, being scheduled for cancer treatment, and self-described as immunocompromised. Anxiety was independently associated with age less than 65 years, delay in oncology care, and self-described as immunocompromised. Depression was independently associated with age less than 65 years, living alone, delay in oncology care, lack of access to counseling, and self-described as immunocompromised ([Table 3](#tbl3){ref-type="table"} ).Table 3Multivariable linear regression predicting cancer worry, anxiety, and depressionCharacteristic\
TermCancer Worry ScaleHADS-AnxietyHADS-Depressionβ coefficient95% CI: low95% CI: high*P* valueβ coefficient95% CI: low95% CI: high*P* valueβ coefficient95% CI: low95% CI: high*P* valueIntercept11.8359.11514.555\<.0017.2174.27310.161\<.0014.3531.7976.909\<.001Age ≥65 y−1.236−2.052−0.42.003−1.016−1.899−0.133.024−0.821−1.588−0.054.036Living alone−0.306−1.2350.622.5170.006−0.9991.011.991.1180.2461.991.012Scheduled for nonsurgical cancer treatment1.1240.2581.99.011−0.203−1.1380.733.6710.409−0.4031.222.322Scheduled for cancer surgery0.764−1.5833.11.523−0.183−2.7242.357.8870.712−1.4932.918.526Delay in oncology care0.604−0.1841.392.1330.9470.0971.797.0290.8130.0751.552.031Medical comorbidity (noncancer)0.504−0.4161.425.2820.876−0.121.872.0850.799−0.0661.663.07Access to counseling (Yes vs no \[referent\])−0.786−1.7330.162.104−0.592−1.6120.428.255−1.148−2.033−0.262.011Self-described as immunocompromised (Yes vs no \[referent\])1.7050.7612.649\<.0011.2950.2782.311.0131.3240.4422.206.003Use of telemedicine (Yes vs no \[referent\])0.754−0.2261.734.131−0.324−1.3790.731.5460.203−0.7131.119.663[^5][^6]

Of 526 responders, 57 (10.8%) reported having a symptom of COVID-19 and 12 (2.3%) underwent COVID-19 testing. Among those tested, 3 had a positive test and 9 had a negative test. Reporting COVID-19 symptoms was not predictive of the CWS score (15 \[6--24\] vs 14 \[6--24\], *P*=.70), HADS-A score (9 \[0--18\] vs 8 \[0--21\], *P*=.102), or HADS-D score (7 \[0--21\] vs 5 \[0--19\], *P*=.074). Participants who had undergone COVID-19 testing reported significantly higher anxiety scores (10.5 \[1--15\] vs 8 \[0--21\], *P*=.012) and depression scores (5.5 \[1--16\] vs 5 \[0--21\], *P*=.05).

Participants were asked to provide, via free text, their top concerns. The most commonly listed concerns among the 469 responding participants included COVID-19 infection (271, 57.8%), cancer recurrence (158, 33.7%), safety of family members (126, 26.9%), access to cancer care (114, 24.3%), financial implications of COVID-19 (78, 16.6%), overall QOL and wellness (62, 13.2%), and social isolation (47, 10.0%) ([Figure 2](#fig2){ref-type="fig"} ).Figure 2Participants' top concerns during the COVID-19 crisis*COVID-19*, coronavirus disease 2019; *ICU*, intensive care unit.*Frey et al. Ovarian cancer during the COVID-19 pandemic. Am J Obstet Gynecol 2020*.

Comment {#sec3}
=======

People living with cancer and providers face unprecedented challenges during the COVID-19 crisis. Our survey of 555 ovarian cancer survivors demonstrates that many have experienced interruptions in their cancer-directed care. Of the participants, 33% reported a delay in at least one component of their cancer care including surgery, nonsurgical cancer-directed therapy, physician appointment, laboratory tests, and imaging. Among the 225 participants scheduled for surgery or chemotherapy, 11% (28) experienced a delay in their cancer treatment. Surgical delays were more common than delays of nonsurgical cancer treatments (26% vs 8%); however, the cohort of women scheduled for surgery was small. These significant interruptions in cancer care are not surprising given that medical staff and resources have been redeployed to manage COVID-19, hospital policies call for cancellation of nonemergent surgical procedures, and general recommendations are to avoid hospital visits because of infection risk and the current strategy of restrictive social distancing.

A total of 89% of participants demonstrated significant cancer worry on CWS. This was a vastly greater proportion than has previously been reported among women with ovarian cancer (88.6% vs 57.9% or 19.3%). However, previous studies of CWS evaluated women after the completion of treatment and our cohort included women during and after treatment.[@bib18] ^,^ [@bib19] In contrast, HADS-A scores indicated that 23.4% of participants completing our survey had abnormal levels of anxiety, which correlates with previously reported levels of clinically abnormal anxiety outside of the COVID-19 time frame (which spanned 13.9%--48.1%). HADS-D scores indicated that 7.6% of participants met the criteria for abnormal depression. This is comparable with the rates of previously published posttreatment HADS-D scores among women both undergoing treatment and having completed treatment, ranging from 5% to 33.7%.[@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25] The pandemic did not seem to negatively affect anxiety and depression; however, these results may be due to our patient population being super users of counseling (56%) and survivor networking (80%) and possibly, as indicated by their willingness to complete a 65-item survey during these times, especially generous, a character trait associated with happiness.[@bib26]

On multivariable regression analysis, age less than 65 years and self-describing as immunocompromised were associated with higher levels of cancer worry, anxiety, and depression. It was surprising to find younger age being associated with increased worry, anxiety, and depression during the COVID-19 crisis because preliminary reports suggest that older age is associated with increased COVID-19 mortality.[@bib27], [@bib28], [@bib29] However, pre--COVID-19 literature on QOL and age for women with ovarian cancer is inconsistent. Several studies confirm our findings that younger age is associated with higher cancer worry, depression, and anxiety, often suggesting that the threat of aggressive illness and its consequences is greater for younger women.[@bib19] ^,^ [@bib21] Other studies have found no difference based on age or even greater depression with older age.[@bib22] ^,^ [@bib25] ^,^ [@bib30] The association between self-describing as immunocompromised and heightened worry, anxiety, and depression was less surprising because the CDC includes individuals who are immunocompromised owing to cancer treatment among those at highest risk for severe COVID-19 illness.[@bib31] Delay in oncology care was predictive of both anxiety and depression. It is important that gynecologic oncologists consider this because, although the intent behind postponing oncology-related appointments may be to minimize COVID-19 infection in a vulnerable patient population, this decision may negatively affect QOL. Interestingly, living in a higher burden COVID-19 state did not negatively affect QOL on any of the measures used, although this may be due to our cohort being composed of a small number of women from low-volume COVID-19 states. Education, cancer stage, and medical comorbidities were not significantly associated with QOL scores.

At the conclusion of the survey, participants were asked to share their top concerns during the COVID-19 pandemic. The most commonly cited concerns were about COVID-19, cancer recurrence, and the safety of family members. The fifth most commonly shared concern, reported by 17% of participants, was the financial implications of the crisis. Limited data on cost of care for ovarian cancer suggest substantial overall costs as well as survivor out-of-pocket expenditure.[@bib32] ^,^ [@bib33] A recent study has reported that individuals with a cancer diagnosis were 2.5 times more likely to file for bankruptcy than individuals without cancer.[@bib34] The country is only beginning to experience the financial implications of COVID-19, and it is critical that the oncology community is attentive to the potential financial toxicity experienced by ovarian cancer survivors.

There are an estimated 233,000 women living with ovarian cancer in the United States, and therefore, our cohort of 555 women represents a small proportion of ovarian cancer survivors.[@bib35] Furthermore, our cohort may not be representative of the greater population of women with ovarian cancer. Women with ovarian cancer who participate in online surveys via survivor networks and Twitter and Facebook groups may be more reflective and informed than those who do not. Those well enough to respond to online survey invitations may represent a limited spectrum of women with current or prior ovarian cancer with computer literacy and access to computers. In addition, most participants identified as non-Hispanic white with extremely limited diversity in race and ethnicity. Emerging data suggest that the COVID-19 pandemic has disproportionately affected many minority and marginalized populations in the United States.[@bib36], [@bib37], [@bib38] All these selection biases could have skewed our findings. Furthermore, as demonstrated in [Figure 1](#fig1){ref-type="fig"}, our cohort tended to live in areas of higher COVID-19 case density, which could certainly affect the generalizability of these results. The survey did not capture information on insurance status, employment, or income, which certainly may affect the impact of COVID-19 on QOL. However, our study did include a large number of women with a current or prior diagnosis of ovarian cancer with diversity in geographic location, age, education, and spectrum on the treatment continuum, and the lessons learned are likely relevant to other people with cancer.

Our findings suggest that ovarian cancer survivors are experiencing delays in cancer-directed treatment during the COVID-19 crisis. Furthermore, women with ovarian cancer participating in this study reported high levels of cancer worry, anxiety, and depression. These components of QOL were negatively affected by younger age, self-described as immunocompromised, and delays in oncology care. Access to counseling services may mitigate some of the depression experienced by these women. People with cancer value communication with their treating oncologist and shared decision making throughout the disease spectrum, especially at times of treatment modifications.[@bib7] ^,^ [@bib8] ^,^ [@bib16] ^,^ [@bib39] Oncologists must therefore remain well informed on the emerging data addressing COVID-19 and cancer, dynamically incorporating the COVID-19 climate into patient care to achieve an acceptable balance between risk of infection and risk of untreated cancer. Furthermore, oncologists must screen patients for their psychosocial well-being and establish a robust framework of patient support, recognizing that communication is a critical clinical tool to improve QOL in these times.
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